Advertisement

Journal of NeuroVirology

, Volume 16, Issue 6, pp 419–426 | Cite as

Foamy virus: an available vector for gene transfer in neural cells and other nondividing cells

  • Yingying Zhang
  • Yongjuan Liu
  • Guoguo Zhu
  • Yanyan Qiu
  • Biwen Peng
  • Jun Yin
  • Wanhong Liu
  • Xiaohua He
Review

Abstract

Foamy viruses (FVs) are classified to a subfamily of retrovirus presented in a wide range of hosts. None of FVs has been found to associate with any diseases in their native hosts. Such a unique biological character of FVs makes it suitable for the development of vectors for gene transfer. However, it is still controversial whether foamy virus vectors (FV vectors) can be applied to the central nervous system (CNS). In this review, we summarize the studies of FV vectors, which have been used for transduction of neural cells and other nondividing cells. We further discuss the potential mechanisms underlying the infection and propose that FVs can be used to develop transfer vectors for gene therapy in neurological disorders.

Keywords

central nervous system foamy virus gene therapy neural cells nondividing cells 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Achong BG, Mansell PW, Epstein MA, Clifford P (1971). An unusual virus in cultures from a human nasopharyngeal carcinoma.J Natl Cancer Inst 46: 299–307.PubMedGoogle Scholar
  2. Bauer TR Jr, Allen JM, Hai M, Tuschong LM, Khan IF, Olson EM, Adler RL, Burkholder TH, Gu YC, Russe DW, Hickstein DD (2008). Successful treatment of canine leukocyte adhesion deficiency by foamy virus vectors.Nat Med 14: 93–97.CrossRefPubMedGoogle Scholar
  3. Blau H, Khavari P (1997). Gene therapy, progress, problems, prospects.Nat Med 3: 612–613.CrossRefPubMedGoogle Scholar
  4. Campbell M, Eng C, Luciw PA (1996). The simian foamy virus type 1 transcriptional transactivator (Tas) binds and activates an enhancer element in the gag gene.J Virol 70: 6847–6855.PubMedGoogle Scholar
  5. Caprariello AV, Miller RH, Selkirk SM (2009). Foamy virus as a gene transfer vector to the central nervous system.Gene Ther 16: 448–452.CrossRefPubMedGoogle Scholar
  6. Delelis O, Lehmann-Che J, Saïb A (2004). Foamy viruses—a world apart.Curr Opin Microbiol 7: 400–406.CrossRefPubMedGoogle Scholar
  7. Enssle J, Jordan I, Mauer B, Rethwilm A (1996). Foamy virus reverse transcriptase is expressed independently from the Gag protein.Proc Natl Acad Sci U S A 93: 4137–4141.CrossRefPubMedGoogle Scholar
  8. Flugel RM, Rethwilm A, Maurer B, Darai G (1987). Nucleotide sequence analysis of the env gene and its flanking regions of the human spumaretrovirus reveal two novel genes.EMBO J 6: 2077–2084.PubMedGoogle Scholar
  9. Flugel RM, Spumaviruses (1991). A group of complex retrovirus.J Acquir Immune Defic Syndr 4: 739–750.PubMedGoogle Scholar
  10. Glorioso JC, Mata M, Fink DJ (2003). Therapeutic gene transfer to the nervous system using viral vectors.J NeuroVirol 9: 165–172.PubMedGoogle Scholar
  11. Hacein-Bey-Abina S, Kalle CV, Schmidt M, Deist FL, Wulffraat N, McIntyre E, Radford I, Villeval JL, Fraser CC, Cavazzana-Calvo M, Fischer A (2003). A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency.N Engl J Med 348: 255–256.CrossRefPubMedGoogle Scholar
  12. Heneine W, Switzer WM, Sandstrom P, Brown J, Vedapuri S, Schable CA, Khan AS, Lerche NW, Schweizer M, Neumann-Haefelin D, Chapman LE, Folks TM (1998). Identification of a human population infected with simian foamy viruses.Nat Med 4: 403–407.CrossRefPubMedGoogle Scholar
  13. Josephson NC, Trobridge G, Russell DW (2004). Transduction of long-term and mobilized peripheral blood-derived NOD/SCID repopulating cells by foamy virus vectors.Hum Gene Ther 15: 87–92.CrossRefPubMedGoogle Scholar
  14. Khan AS (2009). Simian foamy virus infection in humans: prevalence and management.Expert Rev Anti Infect Ther 7: 569–580.CrossRefPubMedGoogle Scholar
  15. Linial M (2000). Why aren’t foamy viruses pathogenic?Trends Microbiol 8: 284–289.CrossRefPubMedGoogle Scholar
  16. Lewis PF, Emerman M (1994). Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus.J Virol 68: 510–516.PubMedGoogle Scholar
  17. Liu W, He X, Cao Z, Sheng J, Liu H, Li Z, Li W (2005). Efficient therapeutic gene expression in cultured rat hippocampal neurons mediated by human foamy virus vectors: a potential for the treatment of neurological diseases.Intervirology 48: 329–335.CrossRefPubMedGoogle Scholar
  18. Liu W, Liu Z, Cao X, Cao Z, Xue L, Zhu F, He X, Li W (2007). Recombinant human foamy virus, a novel vector for neurological disorders gene therapy, drives production of GAD in cultured astrocytes.Mol Ther 15: 1834–1841.CrossRefPubMedGoogle Scholar
  19. Liu W, Liu Z, Liu L, Xiao Z, Cao X, Cao Z, Xue L, Miao L, He X, Li W (2008). A novel human foamy virus mediated gene transfer of GAD67 reduces neuropathic pain following spinal cord injury.Neurosci Lett 432: 13–18.PubMedGoogle Scholar
  20. Lochelt M, Muranyi W, Flugel RM (1993). Human foamy virus genome possesses an internal Bel-1-dependent and functional promoter.Proc Natl Acad Sci U S A 90: 7317–7321.CrossRefPubMedGoogle Scholar
  21. Löchelt M, Yu SF, Linial ML, Flügel RM (1995). The human foamy virus internal promoter is required for efficient gene expression and infectivity.Virology 206: 601–610.CrossRefPubMedGoogle Scholar
  22. Lo YT, Tian T, Nadeau PE, Park J, Mergia A (2010). The foamy virus genome remains unintegrated in the nuclei of G1/S phase-arrested cells, and integrase is critical for preintegration complex transport into the nucleus.J Virol 84: 2832–2842.CrossRefPubMedGoogle Scholar
  23. Lundberg C, Horellou P, Mallet J, Bjorklund A (1996). Generation of DOPA-producing astrocytes by retroviral transduction of the human tyrosine hydroxylase gene: in vitro characterization and in vivo effects in the rat Parkinson model.Exp Neurol 139: 39–53.CrossRefPubMedGoogle Scholar
  24. Marchand F, Jones NG, McMahon SB (2009). Future treatment strategies for neuropathic pain.Handb Exp Pharmacol 194: 589–615.CrossRefPubMedGoogle Scholar
  25. Marshall E (2002). Gene therapy a suspect in leukemia-like disease.Science 298: 34–35.CrossRefPubMedGoogle Scholar
  26. Marshall E (2003). Gene therapy. Second child in French trial is found to have leukemia.Science 299: 320.CrossRefPubMedGoogle Scholar
  27. Maurer B, Bannert H, Darai G, Flugel RM (1988). Analysis of the primary structure of the long terminal repeat and the gag and pol genes of the human spumaretrovirus.J Virol 62: 1590–1597.PubMedGoogle Scholar
  28. Meiering CD, Linial ML (2001). Historical perspective of foamy virus epidemiology and infection.Clin Microbiol Rev 14: 165–176.CrossRefPubMedGoogle Scholar
  29. Meredith A, Mintzer, Simanek EE (2009). Nonviral vectors for gene delivery.Chem Res 109: 259–302.Google Scholar
  30. Mergia A, Chari S, Kolson DL, Goodenow MM, Ciccarone T (2001). The efficiency of simian foamy virus vector type-1 (SFV-1) in nondividing cells and in human PBLs.Virology 280: 243–252.CrossRefPubMedGoogle Scholar
  31. Miller AD, Miller DG, Garcia JV, Lynch CM (1993). Use of retroviral vectors for gene transfer and expression.Methods Enzymol 217: 581–599.CrossRefPubMedGoogle Scholar
  32. Moebes A, Enssle J, Bieniasz PD, Heinkelein M, Lindemann D, Bock M, McClure MO, Rethwilm A (1997). Human foamy virus reverse transcription that occurs late in the viral replication cycle.J Virol 71: 7305–7311.PubMedGoogle Scholar
  33. Morozov VA, Copeland TD, Nagashima K, Gonda MA, Oroszlan S (1997). Protein composition and morphology of human foamy virus intracellular cores and extracellular particles.Virology 228: 307–317.CrossRefPubMedGoogle Scholar
  34. Patton GS, Morris SA, Chung W, Bieniasz PD, McClure MO (2005). Identification of domains in gag important for prototypic foamy virus egress.J Virol 79: 6392–6399.CrossRefPubMedGoogle Scholar
  35. Picard-Maureau M, Kreppel F, Lindemann D, Juretzek T, Herchenröder O, Rethwilm A, Kochanek S, Heinkelein M (2004). Foamy virus-adenovirus hybrid vectors.Gene Therapy 11: 722–728.CrossRefPubMedGoogle Scholar
  36. Rethwilm A (2007). Foamy virus vectors: an awaited alternative to gammaretro- and lentiviral vectors.Curr Gene 7: 261–271.CrossRefGoogle Scholar
  37. Ridet JL, Sarkis C, Serguera C, Zennou V, Charneau P, Mallet J (2003). Transplantation of human adult astrocytes: efficiency and safety requirements for an autologous gene therapy.J Neurosci Res 72: 704–708.CrossRefPubMedGoogle Scholar
  38. Roe T, Reynolds TG, Yu G, Brown PO (1993). Intergration of murine leukemia virus DNA depends on mitosis.EMBO J 12: 2099–2108.PubMedGoogle Scholar
  39. Russell DW, Miller AD (1996). Foamy virus vectors.J Virol 70: 217–222.PubMedGoogle Scholar
  40. Saïb A, Puvion-Dutilleul F, Schmid M, Périès J, de Thé H (1997). Nuclear targeting of incoming human foamy virus Gag proteins involves a centriolar step.J Virol 71: 1155–1161.PubMedGoogle Scholar
  41. Schiephake AW, Rethwilm A (1994). Nuclear localization of foamy virus gag precursor protein.J Virol 68: 4946–4954.Google Scholar
  42. Schweizer M, Falcone V, Gange J, Turek R, Neumann-Haefelin D (1997). Simian foamy virus isolated from an accidentally infected human individual.J Virol 71: 4821–4824.PubMedGoogle Scholar
  43. Schweizer M, Turek R, Hahn H, Schliephake A, Netzer KO, Eder G, Reinhardt M, Rethwilm A, Neumann-Haefelin D (1995). Markers of foamy virus infections in monkeys, apes, and accidentally infected humans: appropriate testing fails to confirm suspected foamy virus prevalence in humans.AIDS Res Hum Retroviruses 11: 161–170.CrossRefPubMedGoogle Scholar
  44. Shi N, Pardridge WM (2000). Noninvasive gene targeting to the brain.Proc Natl Acad Sci U S A 97: 7567–7572.CrossRefPubMedGoogle Scholar
  45. Snyder EY, Senut MC (1997). The use of nonneuronal cells for gene delivery.Neurobiol Dis 4: 69–102.CrossRefPubMedGoogle Scholar
  46. Suzuki Y, Craigie R (2007). The road to chromatin: nuclear entry of retroviruses.Nat Rev Microbiol 5: 187–196.CrossRefPubMedGoogle Scholar
  47. Trobridge G, Josephson N, Vassilopoulos G, Mac J, Russell DW (2002). Improved foamy virus vectors with minimal viral sequences.Mol Ther 6: 321–328.CrossRefPubMedGoogle Scholar
  48. Trobridge G, Russell DW (2004). Cell cycle requirements for transduction by foamy virus vectors compared to those of oncovirus and lentivirus vectors.J Virol 78: 2327–2335.CrossRefPubMedGoogle Scholar
  49. Trobridge GD (2009). Foamy virus vectors for gene transfer.Expert Opin Biol Ther 9: 1427–1436.CrossRefPubMedGoogle Scholar
  50. Verma IM, Somia N (1997). Gene therapy.Nature 389: 239–242.CrossRefPubMedGoogle Scholar
  51. Vile RG, Rusell SJ (1995). Retroviruses as vectors.Br Med Bull 51: 12–30.PubMedGoogle Scholar
  52. Weiss RA (1988) Foamy retroviruses. A virus in search of a disease.Nature 333: 497–498.CrossRefPubMedGoogle Scholar
  53. Wolfe ND, Switzer WM, Carr JK, Bhullar VB, Shanmugam V, Tamoufe U, Prosser AT, Torimiro JN, Wright A, Mpoudi-Ngole E, McCutchan FE, Birx DL, Folks TM, Burke DS, Heneine W (2004). Naturally acquired simian retrovirus infections in central African hunters.Lancet 363: 932–937.CrossRefPubMedGoogle Scholar
  54. Yu SF, Baldwin DN, Gwynn WR, Yendapalli S, Linial ML (1996a). Human foamy virus replication: a pathway distinct from that of retrovirus and hepadnaviruses.Science 271: 1579–1582.CrossRefPubMedGoogle Scholar
  55. Yu SF, Edelman K, Strong RK, Moebes A, Linial ML (1996b). The carboxyl terminus of the human foamy virus Gag protein contains separable nucleic acid binding and nuclear transport domain.J Virol 70: 8255–8262.PubMedGoogle Scholar

Copyright information

© Journal of NeuroVirology 2010

Authors and Affiliations

  • Yingying Zhang
    • 1
  • Yongjuan Liu
    • 1
  • Guoguo Zhu
    • 1
  • Yanyan Qiu
    • 1
  • Biwen Peng
    • 1
  • Jun Yin
    • 1
  • Wanhong Liu
    • 1
  • Xiaohua He
    • 1
  1. 1.School of MedicineWuhan UniversityWuhanP. R. China

Personalised recommendations